Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:

NCT02070523 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: VDCLD regimen

Sponsor

Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

Collaborators

[object Object]